Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bezafibrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 10/20 | 0.77 |
| ▸ | PPARG known ✓ | P37231 | 3/20 | 0.77 |
| ▸ | PPARD known ✓ | Q03181 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | FABP2 | P12104 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bezafibrate SCHEMBL5077755 | 0.88 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL16299 | 0.88 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL22364278 | 0.87 | PPARA (0.98) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL3088387 | 0.87 | PPARA (0.98) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL28565716 | 0.87 | PPARA (0.98) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Bezafibrate SCHEMBL15156489 | 0.84 | PPARA (0.91) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Binifibrate SCHEMBL3654211 | 0.82 | PPARA (0.53) | PPARAPPARGPPARDALDH1A1FABP2 | |
| SCHEMBL12690942 | 0.79 | PPARA (0.82) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Ciprofibrate SCHEMBL26870 | 0.79 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1FABP2 | |
| Ciprofibrate SCHEMBL8164529 | 0.79 | PPARA (1.00) | PPARAPPARGPPARDALDH1A1FABP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5179097-A | Salts of non-steroidal anti-inflammatory carboxylic acids and anti-lipidemic carboxylic acids | ANGRES ISAAC A (US) | 1993-01-12 | — | — | US | claimed |
| US-6630502-B2 | Administering combination of a cholesterol lowering drug and an angiotensin converting enzyme inhibitor for therapy of atherosclerosis | E.R. SQUIBB & SONS, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030149101-A1 | METHOD FOR PREVENTING, STABILIZING OR CAUSING REGRESSION OF ATHEROSCLEROSIS EMPLOYING A COMBINATION OF A CHOLESTEROL LOWERING DRUG AND AN ACE INHIBITOR | E. R. SQUIBB & SONS, INC., A CORP. OF DE | 2003-08-07 | — | — | US | disclosed |
| US-5593971-A | ALONE OR IN COMBINAATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITOR | E. R. SQUIBB & SONS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0457514-B1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | SQUIBB & SONS INC (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5461039-A | Administering squalene synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1995-10-24 | — | — | US | disclosed |
| US-5298497-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1994-03-29 | — | — | US | disclosed |
| US-5190970-A | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1993-03-02 | — | — | US | disclosed |
| US-5130333-A | Mevastatin, lovastatin, pravastatin or velostatin for diabetes and cholesterol reduction | E. R. SQUIBB & SONS, INC. (US) | 1992-07-14 | — | — | US | disclosed |
| EP-0482498-A2 | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1992-04-29 | — | — | EP | disclosed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | disclosed |
| EP-0455042-A1 | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination | E.R. SQUIBB & SONS, INC. (US) | 1991-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149101-A1 | METHOD FOR PREVENTING, STABILIZING OR CAUSING REGRESSION OF ATHEROSCLEROSIS EMPLOYING A COMBINATION OF A CHOLESTEROL LOWERING DRUG AND AN ACE INHIBITOR | HMGCR, ACE, APOB | PPARA 774/4885PPARG 1437/4885PPARD 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.